WO2012093738A1 - 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 - Google Patents
항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 Download PDFInfo
- Publication number
- WO2012093738A1 WO2012093738A1 PCT/KR2011/000010 KR2011000010W WO2012093738A1 WO 2012093738 A1 WO2012093738 A1 WO 2012093738A1 KR 2011000010 W KR2011000010 W KR 2011000010W WO 2012093738 A1 WO2012093738 A1 WO 2012093738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skin
- extract
- lotus leaf
- expression
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000000428 dust Substances 0.000 title abstract description 20
- 230000001627 detrimental effect Effects 0.000 title abstract 2
- 230000003647 oxidation Effects 0.000 title abstract 2
- 238000007254 oxidation reaction Methods 0.000 title abstract 2
- 239000000284 extract Substances 0.000 claims abstract description 70
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 64
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 63
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- 102000016938 Catalase Human genes 0.000 claims abstract description 11
- 108010053835 Catalase Proteins 0.000 claims abstract description 11
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 claims abstract description 10
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims abstract description 10
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims abstract description 10
- 101710168651 Thioredoxin 1 Proteins 0.000 claims abstract description 9
- 101150076311 Prdx1 gene Proteins 0.000 claims abstract description 8
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 claims abstract 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 60
- 210000003491 skin Anatomy 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 210000002510 keratinocyte Anatomy 0.000 claims description 18
- 239000004576 sand Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000009931 harmful effect Effects 0.000 claims description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 11
- 108090000790 Enzymes Proteins 0.000 abstract description 11
- 239000003053 toxin Substances 0.000 abstract description 10
- 231100000765 toxin Toxicity 0.000 abstract description 10
- 108700012359 toxins Proteins 0.000 abstract description 10
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 abstract description 8
- 206010040880 Skin irritation Diseases 0.000 abstract description 7
- 230000036556 skin irritation Effects 0.000 abstract description 7
- 231100000475 skin irritation Toxicity 0.000 abstract description 7
- 238000001784 detoxification Methods 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 240000000233 Melia azedarach Species 0.000 abstract description 3
- 229940088592 immunologic factor Drugs 0.000 abstract description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 abstract description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract 2
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 10
- 102000055779 human DEFB103A Human genes 0.000 description 10
- 210000004209 hair Anatomy 0.000 description 9
- 210000004927 skin cell Anatomy 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 108010086596 glutathione peroxidase GPX1 Proteins 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 108010027853 glutathione S-transferase T1 Proteins 0.000 description 7
- 239000000419 plant extract Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- 229930182566 Gentamicin Natural products 0.000 description 6
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229940116978 human epidermal growth factor Drugs 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229910052956 cinnabar Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- -1 pack Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 101710120040 Antifungal peptide Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 101150115464 GPX1 gene Proteins 0.000 description 1
- 101150111575 GSTT1 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 235000005807 Nelumbo Nutrition 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 101710149118 Quinone oxidoreductase 1 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Definitions
- the present invention relates to a composition for mitigating the harmful effects of skin for antioxidants and yellow dust, and more particularly to a composition having an antioxidant effect for reducing the harmful effects of skin caused by yellow dust and lotus leaf as an active ingredient. .
- the skin is a part of the body that is directly exposed to the external environment. It not only acts as a protective shield for important organs in our body, but also regulates water evaporation and protects the body from external infections.
- skin that prevents virus penetration from the outside when exposed to excessive ultraviolet rays or contaminants, causes skin irritation and inflammatory reactions such as erythema, edema and itching.
- Skin trouble caused by these environmentally harmful factors is not only aesthetic problem, but increased oxygen species, which can't be handled by the cell's antioxidant protection system, harms DNA, proteins, fats, sugars, and the survival, growth, and differentiation of cells. Affects and may cause cell death.
- Yellow sand is a phenomenon in which small sand or ocher is floating in the deserts inland, such as China and Mongolia, and is transported away by upper winds and falls near the ground. In Korea, yellow dust occurs periodically every spring. Yellow sand is a complex of organic and inorganic materials, and its physical characteristics and composition vary greatly depending on the time and place of occurrence, and it also contains metal components that can affect biologically. Larger particles in the yellow dust stay mainly at or near the source, and most of them are particulate matter (Pm10) with a diameter of less than 10 ⁇ m.
- Pm10 particulate matter
- Keratinocytes Keratinocytes in the outermost layers of the skin interact with immune cells, mainly in fibroblasts, endothelial cells and dermal cells, and play an important role in the initiation, control and regulation of skin irritation.
- Skin irritation is the most common adverse effect associated with subcutaneous inflammatory reactions, and clinically 70% of contact dermatitis can be explained by skin irritation.
- Erythema, edema, cracks, water loss, epidermis dropouts, epilepsy and pain are the typical symptoms of irritant or allergic contact dermatitis. These are the symptoms of abnormal cell homeostasis and inflammatory reactions.
- There has been little research on skin irritation related to yellow dust but as the frequency of yellow dust increased, it was very necessary to develop natural external preparations to prevent or treat skin irritation caused by yellow dust.
- the present invention provides an antioxidant composition containing the extract of Geunpi as an active ingredient.
- the composition may further contain a lotus leaf extract.
- the composition may be characterized by inhibiting the generation of reactive oxygen species or increasing the expression of antioxidant protein genes.
- the present invention also provides a composition for alleviating the harmful effects of skin by yellow sand containing the extract of lotus bark and lotus leaf extract as an active ingredient.
- the composition may be characterized by increasing the expression of GST, NQO1 or hBD3.
- the present invention increases the expression of toxin detoxifying enzyme NQO1, toxin-releasing enzyme GSTT1 to detoxify and excrete toxins, protects the skin by increasing the expression of natural anti-fungal peptide hBD3, GPX1, By increasing the expression of antioxidant proteins of catalase, Trx1 and Prdx1, it protects the skin and inhibits aging by inhibiting the production of free radicals.This composition prevents trouble caused by yellow dust, skin protection and aging treatment. And prophylactic pharmaceutical or cosmetic compositions.
- 1 is a graph showing the amount of free radicals generated when a composition according to an embodiment of the present invention is treated to human normal keratinocytes.
- Figure 5 shows the results of polymerase chain reaction (RT-PCR) analysis confirming the expression level of GPX1, catalase (catalase), Trx1, Prdx1 when the composition according to an embodiment of the present invention treated human normal keratinous skin cells It is a graph.
- the present invention provides an antioxidative composition containing the extract of Gyunpi as an active ingredient.
- Cinnabar bark refers to the bark or root bark of the mulberry tree (also called Melia azedarach L. var. Japonica Makino). . It is also used for skin eczema and has diuretic and antipyretic effects. The pharmacological action has been reported to be effective in eliminating intestinal worms and trichomonas vaginitis such as tapeworm pharmaceuticals and congregation, but no antioxidant effect has been reported. It is curved semi-tubular or tubular, and its outer surface is gray brown, and has long vertically torn patterns and horizontal trees, and the cork layer is reddish brown. The face is yellowish white and fibrous, and the quality is hard but easy to bend. This drug is good for bark with a lot of cortex. Other names include the lotus root bark, lotus bark, lotus bark bark, Geumnyeongja ( ⁇ ⁇ ).
- composition of the present invention may further contain a lotus leaf extract, in addition to Kokpi.
- Lotus flower also known as Nelumbo nuficera
- Nelumbo nuficera is a perennial aquatic plant with yellow flowers. It is widely used as a food ingredient and used in various medicines in eastern Asia, especially China. Specifically, lotus seeds are applied to various applications such as tissue inflammation, cancer and leprosy treatment, and poisons. Lotus embryos have also been reported to relieve acute inflammation in vivo. Lotus leaf is also used as a traditional Chinese medicine with hemostatic action, and is known to relieve hyperlipidemia in experimental animals.
- the extract of lotus leaf or lotus leaf used in the present invention is not particularly limited, and the extract can be obtained with water or an organic solvent.
- the organic solvent used in the present invention may be one or more selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform, or a mixed solvent of these organic solvents and water may be used.
- the one purchased from the Korea Plant Extract Bank was used.
- the extract of lotus bark or lotus leaf prepared by the above method is preferably contained in an amount of 1 to 30% by weight based on the total weight of the composition. If the total amount of the extract is less than 1% by weight, the effect is insignificant, and if the total amount is more than 30% by weight, stability may be caused.
- composition containing the extract of the extract of the present invention as an active ingredient and the composition simultaneously containing the extract of the extract of lotus and lotus leaf have an antioxidant effect.
- ROS Reactive Oxygen Species
- the antioxidant effect can be achieved by increasing the expression of the antioxidant protein gene.
- the antioxidant protein genes include, but are not limited to, GPX1, catalase, Trx1, and Prdx1.
- Glutathione peroxidase 1 is one of several types of glutathione peroxidase (GPX), an enzyme encoded by the GPX1 gene in the human body. Glutathione peroxidase is involved in the detoxification of hydrogen peroxidase and is one of the most important antioxidant enzymes in the human body. As an example of this protein sequence, Hs00829989_Gh is mentioned.
- Catalase is a common enzyme found in almost all organisms that catalyzes the breakdown of hydrogen peroxidase into water and oxygen.
- An example of the sequence of the protein is Hs00156308_m1.
- Thioredoxin 1 is a cytoplasmic thioredoxin isoenzyme of the thioredoxin system that protects cells from oxidative and reductive stress.
- Hs01555212_g1 is mentioned.
- Peroxiredoxin 1 is a protein encoded by the PRDX 1 gene in the human body. As an example of this protein sequence, Hs00602020_Mh is mentioned.
- the present invention provides a composition for alleviating harmful effects of skin by yellow sand containing the extract of lotus bark and lotus leaf extract as an active ingredient. More specifically, the composition of the present invention may be to mitigate the harmful effects on the normal keratinocytes (Keratinocyte) of the skin.
- each of the genes GST, NQO1, hBD3, and each gene is contained when the lotus leaf or the extract of lotus leaf is contained. It can be seen that the expression of significantly increased.
- GSTT1 is an enzyme that releases toxins
- NQO1 is an enzyme that detoxifies
- hBD3 is a skin antimicrobial peptide that is a natural immune factor, and when the expression of detoxification-related enzymes including GST, NQO1 or hBD3 increases, Protect your skin.
- Glutathione S-transferase is a protein present in vivo and is divided into five classes. One of them, glutathione S-transferase theta-1 (GSTT1), is an enzyme encoded by the GSTT1 gene that catalyzes the conjugation of reduced glutathione to various electrophilic and hydrophobic compounds. .
- GSTT1 glutathione S-transferase theta-1
- Hs00184475_m1 is mentioned.
- Quinone oxidoreductase 1 (NQ01) is a protein in vivo that catalyzes two electron reductions of quinones. This enzyme protects the living body against quinone-mediated carcinogenicity and activates a bioreducible alkylating agent.
- Hs01045994_m1 is mentioned.
- Human Beta Defensin 3 induces migration and activation of antigen presenting cells and functions as an immune enhancer.
- hBD3 Human Beta Defensin 3
- composition according to the present invention may be a cosmetic composition, a pharmaceutical composition or a health food composition.
- the cosmetic composition is not particularly limited to the formulation, softening longevity, astringent makeup, nourishing longevity, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing lotion, cleansing foam, cleansing water, pack, Essences, powders, body lotions, body creams, body oils, body essences, body cleaners, hair dyes, hair tonics, hair nourishing cosmetics, hair essences, hair serums, scalp treatments, hair treatments, hair conditioners, hair shampoos, hair lotions , Toothpaste, mouthwash, hair dresser, wool, lotion, ointment, gel, cream, patch or spray, and the like.
- the pharmaceutical composition may further contain pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances, and various oral methods according to conventional methods. It may be formulated in the form of a dosage form or parenteral dosage form.
- pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances, and various oral methods according to conventional methods. It may be formulated in the form of a dosage form or parenteral dosage form.
- the oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, and granules, and these formulations may contain diluents (e.g., lactose, dextrose, water, etc.) in addition to the active ingredients.
- diluents e.g., lactose, dextrose, water, etc.
- Cross mannitol, sorbitol, cellulose and glycine
- lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols.
- Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
- binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt
- Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
- the tablets can be prepared by conventional mixing, granulating or coating methods.
- parenteral administration agent may be, for example, an external preparation for skin, and may be a lotion, ointment, gel, cream, patch or spray formulation, but is not limited thereto.
- the health food composition is not particularly limited in the formulation, for example, it may be formulated as a tablet, granules, drinks, caramel, diet bar and the like.
- the health food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use, in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials. .
- the dosage of the active ingredient is within the level of those skilled in the art, and the daily dosage of the drug depends on various factors such as less progression, onset, age, health condition, complications, etc. of the subject to be administered.
- the composition may be administered by dividing the composition 1 to 500 mg / kg, preferably 30 to 200 mg / kg, once or twice a day, and the dosage may be in the range of the present invention by any method. It is not limiting.
- Human epidermal neonatal keratinocyte cells are a commercially available and recommended method, purchased from Lonza, Inc., Walkersville, MD, and passaged before CO 2 incubator Cells were incubated at 37 ° C. and 5% CO 2 in a CO 2 incubator. Cell cultures were cultured according to Lonza's instructions.
- KGM-2 Bullet Kit Bovine pituitary extract (BPE), 0.5 ml of human epidermal growth factor (hEGF), 0.5 ml of insulin (Insulin), hydrocortisone) 0.5 ml of hydrocortisone, 0.5 ml of Transferrin, 0.5 ml of Epinephrine, and 0.5 ml of Gentamycin Sulfate + Amphofericin-B (Gentamycin Suflate + Amphofericin-B: GA-1000) were used.
- the extract of lotus leaf and lotus leaf inhibits the production of free radicals increased by yellow sand in human normal keratin skin cells, especially when the extract of lotus leaf and lotus leaf is simultaneously contained. It was confirmed that the inhibitory effect appeared more remarkably due to the effect.
- top horny skin cells Human epidermal neonatal keratinocyte cells
- Rhone its CO 2 incubator CO 2 incubator
- 37 °C, 5% CO 2 conditions The cells were cultured under.
- Cell cultures were cultured according to Lonza's instructions.
- KGM-2 Bullet Kit Bovine pituitary extract (BPE), 0.5 ml of human epidermal growth factor (hEGF), 0.5 ml of insulin (Insulin), hydrocortisone) 0.5 ml of hydrocortisone, 0.5 ml of Transferrin, 0.5 ml of Epinephrine, and 0.5 ml of Gentamycin Sulfate + Amphofericin-B (Gentamycin Suflate + Amphofericin-B: GA-1000) were used.
- RNA total RNA
- Trizol Invitrogen
- the separated RNA was purified once more using KIAGEN's RNA kit, and then the quality of RNA was confirmed using Agilent's BioAnalyzer 2100 model instrument.
- CDNA was synthesized from the isolated RNA using Invitrogen's Superscript Reverse Transcriptase (RT) II kit, which was used for real time-reverse transcription polymerase chain reaction (Q-RT-). Quantitatively by PCR).
- RT Superscript Reverse Transcriptase
- the mixed treatment of extract of lotus leaf or lotus leaf has an effect of increasing toxin detoxification, excretion and expression of natural immune factors due to synergistic effects.
- top horny skin cells Human epidermal neonatal keratinocyte cells
- Rhone its CO 2 incubator CO 2 incubator
- 37 °C, 5% CO 2 conditions The cells were cultured under.
- Cell cultures were cultured according to Lonza's instructions.
- KGM-2 Bullet Kit Bovine pituitary extract (BPE), 0.5 ml of human epidermal growth factor (hEGF), 0.5 ml of insulin (Insulin), hydrocortisone) 0.5 ml of hydrocortisone, 0.5 ml of Transferrin, 0.5 ml of Epinephrine, and 0.5 ml of Gentamycin Sulfate + Amphofericin-B (Gentamycin Suflate + Amphofericin-B: GA-1000) were used.
- RT Superscript Reverse Transcriptase
- GPX1, catalase, Trx1, Prdx1 was about 3.0, 2.43, 2.48, 2.4, respectively, it was found that the highest expression.
- antioxidant enzymes not only increased when the extract of the bark extract was added, but also increased when the extracts of the bark and lotus leaf extracts were simultaneously treated.
- composition of this invention is not limited only to this example.
- Xanthan gum (2% aqueous solution) 2.00
Abstract
Description
Claims (9)
- 고련피 추출물을 유효성분으로 함유하는 항산화용 조성물.
- 제 1항에 있어서,상기 조성물은 연꽃잎 추출물을 더 함유하는 것인 조성물.
- 제 1항 또는 제 2항에 있어서,상기 조성물은 활성산소종 생성을 억제함을 특징으로 하는 조성물.
- 제 1항 또는 제 2항에 있어서,상기 조성물은 항산화 단백질 유전자의 발현을 증가시킴을 특징으로 하는 조성물.
- 제 4항에 있어서,상기 항산화 단백질 유전자는 GPX1, 카탈라아제(catalase), Trx1 및 Prdx1를 포함하는 것인 조성물.
- 고련피 추출물 및 연꽃잎 추출물을 유효성분으로 함유하는 황사에 의한 피부 유해영향 완화용 조성물.
- 제 6항에 있어서,상기 조성물은 GST, NQO1 또는 hBD3의 발현을 증가시킴을 특징으로 하는 조성물.
- 제 1항, 제 2항 및 제 6항 중 어느 한 항에 있어서,상기 조성물은 피부의 정상각질세포(Keratinocyte)에 미치는 유해영향을 완화하는 것을 특징으로 하는 조성물.
- 제 1항, 제 2항 및 제 6항 중 어느 한 항에 있어서,상기 추출물의 총량은 조성물 총 중량에 대하여 1 내지 30 중량%인 것인 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180068574.7A CN103415299B (zh) | 2011-01-03 | 2011-01-03 | 用于抗氧化和减轻由亚洲沙尘对皮肤造成的有害作用的组合物 |
KR1020137016899A KR101637973B1 (ko) | 2011-01-03 | 2011-01-03 | 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 |
PCT/KR2011/000010 WO2012093738A1 (ko) | 2011-01-03 | 2011-01-03 | 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 |
SG2013051024A SG191808A1 (en) | 2011-01-03 | 2011-01-03 | Composition for combating oxidation and alleviating detrimental effects on skin caused by asian dust |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2011/000010 WO2012093738A1 (ko) | 2011-01-03 | 2011-01-03 | 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012093738A1 true WO2012093738A1 (ko) | 2012-07-12 |
Family
ID=46457585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/000010 WO2012093738A1 (ko) | 2011-01-03 | 2011-01-03 | 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR101637973B1 (ko) |
CN (1) | CN103415299B (ko) |
SG (1) | SG191808A1 (ko) |
WO (1) | WO2012093738A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102040230B1 (ko) * | 2017-09-25 | 2019-11-04 | 제주대학교 산학협력단 | 푸르푸로갈린을 포함하는, 활성산소종, 자외선 또는 미세먼지에 대한 피부 보호용 화장료 조성물 |
KR102041485B1 (ko) * | 2017-09-25 | 2019-11-06 | 제주대학교 산학협력단 | 3,4-디-카페오일퀴닌산을 포함하는, 활성산소종, 자외선 또는 미세먼지에 대한 피부 보호용 화장료 조성물 |
KR102091923B1 (ko) | 2018-03-15 | 2020-03-20 | 에스케이바이오랜드 주식회사 | 부평초 추출물을 유효성분으로 함유하는 피부 손상 개선 또는 보호용 화장료 조성물 |
KR102257477B1 (ko) * | 2019-07-25 | 2021-05-31 | 주식회사 더가든오브내추럴솔루션 | 연잎 추출물을 유효성분으로 함유하는 안티-폴루션 효과를 가지는 화장료 조성물 |
CN112956569A (zh) * | 2021-03-17 | 2021-06-15 | 国健药业(深圳)集团有限公司 | 一种玉竹养颜茶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060100115A (ko) * | 2005-03-16 | 2006-09-20 | 주식회사 해피어스화장품 | 연꽃 추출물을 주요성분으로 하여 항산화 효과를 가지는화장료 조성물 |
KR100815873B1 (ko) * | 2007-04-18 | 2008-03-28 | 대구한의대학교산학협력단 | 항산화 효과를 갖는 가죽나무 추출물을 유효성분으로함유하는 화장료 조성물 |
KR20100128807A (ko) * | 2009-05-29 | 2010-12-08 | (주)아모레퍼시픽 | 피부 세포의 역동성 활성화를 위한 화장료 조성물 |
-
2011
- 2011-01-03 WO PCT/KR2011/000010 patent/WO2012093738A1/ko active Application Filing
- 2011-01-03 SG SG2013051024A patent/SG191808A1/en unknown
- 2011-01-03 KR KR1020137016899A patent/KR101637973B1/ko active IP Right Grant
- 2011-01-03 CN CN201180068574.7A patent/CN103415299B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060100115A (ko) * | 2005-03-16 | 2006-09-20 | 주식회사 해피어스화장품 | 연꽃 추출물을 주요성분으로 하여 항산화 효과를 가지는화장료 조성물 |
KR100815873B1 (ko) * | 2007-04-18 | 2008-03-28 | 대구한의대학교산학협력단 | 항산화 효과를 갖는 가죽나무 추출물을 유효성분으로함유하는 화장료 조성물 |
KR20100128807A (ko) * | 2009-05-29 | 2010-12-08 | (주)아모레퍼시픽 | 피부 세포의 역동성 활성화를 위한 화장료 조성물 |
Non-Patent Citations (1)
Title |
---|
CHAN HEO ET AL., THE JOURNAL OF APPLIED PHARMACOLOGY, vol. 11, 2003, pages 196 - 199 * |
Also Published As
Publication number | Publication date |
---|---|
CN103415299B (zh) | 2017-02-08 |
KR101637973B1 (ko) | 2016-07-11 |
CN103415299A (zh) | 2013-11-27 |
SG191808A1 (en) | 2013-08-30 |
KR20130132508A (ko) | 2013-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8158161B2 (en) | Methods and pharmaceutical compositions useful for treating psoriasis | |
WO2019103329A1 (ko) | 갈색거저리 발효 추출물을 유효성분으로 포함하는 항산화용 조성물 | |
WO2012093738A1 (ko) | 항산화용 및 황사에 의한 피부 유해영향 완화용 조성물 | |
WO2011122869A2 (ko) | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 | |
KR101132246B1 (ko) | 진세노사이드 알지3와 알에이치2를 주성분으로 하는 발모 촉진용 화장료 조성물 및 그를 함유하는 모발 화장제 | |
WO2014175678A1 (ko) | 진세노사이드 rg3를 함유하는 피부 외용제 조성물 | |
KR101655146B1 (ko) | 식물 당단백질 추출물을 함유하는 조성물 | |
WO2011096688A2 (ko) | 디벤조-р-디옥신 유도체를 포함하는 두피 및 모발 건강 개선용 조성물 | |
WO2019074256A1 (ko) | 두피노화 예방 및 완화, 및 탈모방지 효과가 있는 화장료 조성물 | |
WO2011108907A2 (ko) | 한방추출물을 유효성분으로 함유하는 소양증 및 아토피 개선용 조성물 | |
KR20180081327A (ko) | 사삼 추출물을 유효성분으로 포함하는 피부외용제 조성물 | |
CN113350232B (zh) | 含马齿苋、艾叶及红景天的混合提取物作为有效成分的皮肤保护及刺激缓解用化妆品组合物 | |
KR101601865B1 (ko) | 꽃가루, 집먼지 진드기 또는 황사에 의한 피부 유해반응을 스크리닝하는 방법 및 이를 조절하는 피부 외용제 조성물 | |
WO2014175676A1 (ko) | 진세노사이드 rf를 함유하는 피부 외용제 조성물 | |
KR100525722B1 (ko) | 피부외용제 | |
WO2019190010A1 (ko) | 피부 주름 개선, 보습, 항산화 및 염증 완화 효과가 증가된 진피, 후박, 현호색, 아선약의 에탄올 추출 조성물 | |
JP2002526395A (ja) | 化粧品あるいは皮膚科製品におけるボルド抽出物の使用 | |
KR101698924B1 (ko) | 식물 당단백질 추출물을 함유하는 조성물 | |
KR101715202B1 (ko) | 식물 당단백질 추출물을 함유하는 조성물 | |
WO2019059527A1 (ko) | 매화꽃 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
WO2017138692A1 (ko) | 어리연꽃 속 식물의 추출물을 포함하는 피부 개선용 화장료 조성물 | |
KR102360618B1 (ko) | 목단화 및 일라이트를 유효성분으로 포함하는 화장료 조성물 | |
WO2023282367A1 (ko) | 백미추출물을 포함하는 화장료 조성물 | |
KR20140145268A (ko) | 모공 수렴 및 여드름 균 억제 기능을 갖는 화합물이 포함된 화장료 조성물 | |
WO2023022272A1 (ko) | 쐐기풀을 포함하는 기능성 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11854561 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20137016899 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1301003757 Country of ref document: TH |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 10/09/2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11854561 Country of ref document: EP Kind code of ref document: A1 |